Obeticholic Acid in Bariatric and Gallstone Disease (OCABSGS)

Sahlgrenska University Hospital

Status and phase: Completed; Phase 2

Conditions: Gallstones; Obesity

Treatments: Drug: Placebo; Drug: Obeticholic acid

Study type: Interventional

Funder types: Other

Identifiers

NCT01625026

OCABSGS

Details and patient eligibility

About

By binding to the nuclear receptor FXR, bile acids not only regulate their own turn-over but presumably also pivotal steps in cholesterol, triglyceride and glucose metabolism as shown in laboratory animals. Obeticholic acid (OCA) is a semisynthetic bile acid with very high affinity to FXR. In a pharmacodynamic study the effects of OCA on bile acid, lipid and glucose turn-over are studied in 20 morbidly obese and 20 gallstones patents, respectively, that are administered OCA at 25 mg/day in three weeks before bariatric (BS) or gallstone (GS) surgery where in addition to blood samples also biopsies are taken from the liver and in the case of BS, omental and subcutaneous adipose tissue and in case of GS, gallbladder bile.

Full description

In a placebo-controlled double-blind randomized trial, 20 otherwise healthy morbidly obese patients scheduled for bariatric surgery, and 20 otherwise healthy gallstone patients will be administered 25 mg/day INT-747 or placebo for three weeks until the day before surgery. Serum from days 1 and 21 will be analyzed for routine liver tests, bile acids, a complete lipid profile including FA and in addition for 7α-hydroxy-4-cholesten-3-one and FGF-19, markers for bile acid synthesis and its intestinal stimulation. For the evaluation of insulin resistance and possible pre-diabetes, plasma will be taken for the estimation of HOMA index and oral glucose tolerance test (OGTT) will be performed at days 1 and 21. At surgery, a liver biopsy (0.5-1 g) and a white adipose tissue (WAT) specimen (1 cm2) will be taken and immediately frozen in liquid nitrogen for mRNA and protein preparation for quantitative RT-PCR and Western analysis, respectively, histopathological NAFLD grading, and measuring of hepatic and WAT lipase activity. In gallstone patients, gallbladder bile will be sampled for the measurements of biliary lipids (cholesterol, phospholipids, bile acids) and the calculation of the cholesterol saturation index.

Enrollment: 40 patients

Sex: All

Ages: 20 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• In the obesity group: BMI ≥35 kg/m2
• In the gallstone group: symptomatic, ultrasound verified gallstone disease

Exclusion criteria

• Chronic liver disease other than NAFLD (viral hepatitis, autoimmune liver disease, hemochromatosis, homozygous alpha1-antitrypsin deficiency and Wilson disease)
• Previous gastric or small bowel surgery
• Inflammatory bowel disease
• Uncontrolled diabetes mellitus (fasting blood glucose >6.7 mmol/L), hypothyroidism or hyperthyroidism, or other significant endocrine disease.
• Pregnancy. A urine pregnancy test will be performed the day before start of medication. Women of childbearing potential can only be included if a safe and reliable contraception is used, e.g., oral contraceptives.
• Elevations of transaminases (ALAT/ASAT) or alkaline phosphatase or bilirubin above 2xULN (upper limit of normal) the day before start of medication.
• Other serious disease, including depressive disorders treated by medication
• Patients who will not comply with the protocol.
• A subject who is euthyroid on a stable replacement dose of thyroid hormone is acceptable provided the TSH is within normal range.

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

40 participants in 4 patient groups, including a placebo group

Morbid Obesity OCA

Active Comparator group

Description:

Obeticholic acid 25 mg/day in three weeks

Treatment:

Drug: Obeticholic acid

Morbid Obesity Placebo

Placebo Comparator group

Description:

Obeticholic acid 25 mg/day matching placebo in three weeks

Treatment:

Drug: Placebo

Gallstones OCA

Active Comparator group

Description:

Obeticholic acid 25 mg/day in three weeks

Treatment:

Drug: Obeticholic acid

Gallstones Placebo

Placebo Comparator group

Description:

Obeticholic acid 25 mg/day matching placebo in three weeks

Treatment:

Drug: Placebo